Sugi Predict

Sugi Predict / Compounds / SCHEMBL692397

SCHEMBL692397

SCHEMBL692397

Cc1ccc(-c2ccccc2)c(N)c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.48
▸ ESR2 Q92731 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ CYP2A6 P11509 2/20 0.42
▸ CYP2B6 P20813 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ CYP3A4 P08684 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ HBB P68871 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ SENP6 Q9GZR1 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PDCD1 Q15116 1/20 0.38
▸ CD274 Q9NZQ7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31111778 1.00 POLB (0.48) POLBESR2ALDH1A1HSD17B10CYP2A6
SCHEMBL5440206 0.88 ALDH1A1 (0.43) POLBESR2ALDH1A1HSD17B10MAPT
SCHEMBL2458337 0.84 POLB (0.50) POLBESR2ALDH1A1HSD17B10CYP2A6
SCHEMBL28845278 0.83 HSD17B10 (0.48) POLBESR2ALDH1A1HSD17B10CYP2A6
SCHEMBL10935618 0.83 POLB (0.67) POLBESR2ALDH1A1HSD17B10CYP2A6
SCHEMBL397459 0.83 POLB (0.48) POLBALDH1A1HSD17B10MAPTCYP3A4
SCHEMBL31607617 0.83 POLB (0.48) POLBALDH1A1HSD17B10MAPTCYP3A4
SCHEMBL28424987 0.82 POLB (0.48) POLBESR2ALDH1A1HSD17B10CYP2A6
SCHEMBL3784859 0.80 MAOA (0.45) POLBALDH1A1CYP3A4TSHRNPC1
SCHEMBL31607612 0.80 MAOA (0.45) POLBALDH1A1CYP3A4TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101812304-B Liquid crystal aligning agent, liquid crystal display device and fabricating method thereof JSR CO LTD 2014-03-19 — — CN claimed
US-20240025902-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE BEONE MEDICINES I GMBH (CH) 2024-01-25 — — US disclosed
US-11739103-B2 Processes for preparing a pan-JAK inhibitor and related intermediate compounds Theravance Biopharma R&D LP, LLC (US) 2023-08-29 — — US disclosed
CN-115551497-A Compounds with immunomodulatory activity and therapeutic uses thereof 普渡研究基金会 2022-12-30 — — CN disclosed
US-20220112219-A1 PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2022-04-14 — — US disclosed
EP-3746079-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS Bayer Aktiengesellschaft (DE) 2020-12-09 — — EP disclosed
CN-110461830-A Selective inhibitors of JAK1 ASTRAZENECA AB 2019-11-15 — — CN disclosed
CN-110357911-A A kind of rape element sterol derivatization reagent and its preparation method and application 武汉大学 2019-10-22 — — CN disclosed
CN-110248937-A 4, 5-Cyclic 1,2, 4-triazolones 拜耳股份有限公司 2019-09-17 — — CN disclosed
WO-2019149637-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2019-08-08 — — WO disclosed
WO-2010124042-A2 MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-10-28 — — WO disclosed
CN-101836155-A Liquid crystal aligning agent, method for forming liquid crystal alignment film and liquid crystal display device JSR CORP 2010-09-15 — — CN disclosed
CN-101730862-A Liquid crystal aligning agent, liquid crystal alignment film, method for producing the same, and liquid crystal display device JSR CORP 2010-06-09 — — CN disclosed
EP-2121703-A1 THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS AstraZeneca AB (SE) 2009-11-25 — — EP disclosed
EP-2094662-A1 POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS Astellas Pharma Inc. (JP) 2009-09-02 — — EP disclosed
CN-101515092-A Aligning agent for liquid crystal and liquid crystal display element JSR CORP (JP) 2009-08-26 — — CN disclosed
WO-2008072784-A1 POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS ASTELLAS PHARMA INC. (JP) 2008-06-19 — — WO disclosed
WO-2008020799-A1 THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS ASTRAZENECA AB (SE) 2008-02-21 — — WO disclosed
EP-1730114-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GLAXO GROUP LIMITED (GB) 2006-12-13 — — EP disclosed
WO-2005087746-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GLAXO GROUP LIMITED (GB) 2005-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112219-A1 PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS JAK1, JAK3, JAK2 POLB 1003/4885ESR2 4580/4885ALDH1A1 2732/4885
US-20240025902-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE EGFR, ERBB2, CBL POLB 2395/4885ESR2 593/4885ALDH1A1 3514/4885
US-11739103-B2 Processes for preparing a pan-JAK inhibitor and related intermediate compounds JAK1, JAK3, JAK2 POLB 1003/4885ESR2 4580/4885ALDH1A1 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.